Arkolith/Insider Trading/TBPH/Form 4/A

Broshy Eran

DirectorTheravance Biopharma, Inc. (TBPH) · full profile →Form 4/A · filed Nov 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$809K
Net Open-Market Flow
-$809K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 11, 2025Sell(S)14K$18.50$259K60K
Nov 11, 2025Sell(S)16K$18.50$287K76K
Nov 11, 2025Sell(S)16K$17.00$264K60K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 11, 2025Option exercise(M)14K$10.15$142K108K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001256230-25-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML

Keep exploring

Connected pages for Theravance Biopharma, Inc.

Build

Ask your agent about TBPH insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001256230-25-000007"
Ask your agent
Use Arkolith to summarize insider buying and selling at Theravance Biopharma, Inc.
over the last 90 days and cite the filings.